Drug interaction study tests how bosentan changes levels of experimental pill
NCT ID NCT05723874
First seen Nov 01, 2025
Summary
This completed Phase 1 trial enrolled 14 healthy men to see how taking bosentan (a drug for high blood pressure in the lungs) changes the amount of BI 425809 (iclepertin) in the blood. Participants took BI 425809 alone for 10 days, then both drugs together for 14 days. The study measured drug levels but did not test any treatment for a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 425809 (iclepertin) and bosentan
What this could lead to
If successful, this study could help doctors understand how to dose iclepertin safely when taken with bosentan or similar drugs.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels, not whether the drug works for any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.